메뉴 건너뛰기




Volumn 21, Issue 24, 2015, Pages 5415-5416

Optimizing Anti-EGFR Therapy in Colorectal Cancer

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; RAMUCIRUMAB; REGORAFENIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN;

EID: 84954119958     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1768     Document Type: Article
Times cited : (7)

References (12)
  • 1
    • 84954163383 scopus 로고    scopus 로고
    • Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer
    • Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Can Res 2015;21: 5469-79.
    • (2015) Clin Can Res , vol.21 , pp. 5469-5479
    • Peeters, M.1    Oliner, K.S.2    Price, T.J.3    Cervantes, A.4    Sobrero, A.F.5    Ducreux, M.6
  • 2
    • 84937143954 scopus 로고    scopus 로고
    • Metastatic colorectal cancer: Current state and future directions
    • Fakih MG. Metastatic colorectal cancer: Current state and future directions. J Clin Oncol 2015;33:1809-24.
    • (2015) J Clin Oncol , vol.33 , pp. 1809-1824
    • Fakih, M.G.1
  • 5
    • 84906846009 scopus 로고    scopus 로고
    • Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: Findings from the CAPRI-GOIM trial
    • Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: Findings from the CAPRI-GOIM trial. Ann Oncol 2014;25:1756-61.
    • (2014) Ann Oncol , vol.25 , pp. 1756-1761
    • Ciardiello, F.1    Normanno, N.2    Maiello, E.3    Martinelli, E.4    Troiani, T.5    Pisconti, S.6
  • 6
    • 77955277111 scopus 로고    scopus 로고
    • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
    • De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
    • (2010) Lancet Oncol , vol.11 , pp. 753-762
    • De Roock, W.1    Claes, B.2    Bernasconi, D.3    De Schutter, J.4    Biesmans, B.5    Fountzilas, G.6
  • 7
    • 84925324704 scopus 로고    scopus 로고
    • Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer
    • Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015;33: 692-700.
    • (2015) J Clin Oncol , vol.33 , pp. 692-700
    • Van Cutsem, E.1    Lenz, H.J.2    Kohne, C.H.3    Heinemann, V.4    Tejpar, S.5    Melezinek, I.6
  • 8
    • 84929463919 scopus 로고    scopus 로고
    • Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy
    • Laurent-Puig P, Pekin D, Normand C, Kotsopoulos SK, Nizard P, Perez-Toralla K, et al. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res 2015;21:1087-97.
    • (2015) Clin Cancer Res , vol.21 , pp. 1087-1097
    • Laurent-Puig, P.1    Pekin, D.2    Normand, C.3    Kotsopoulos, S.K.4    Nizard, P.5    Perez-Toralla, K.6
  • 9
    • 84878862323 scopus 로고    scopus 로고
    • Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
    • Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013;3:658-73.
    • (2013) Cancer Discov , vol.3 , pp. 658-673
    • Bardelli, A.1    Corso, S.2    Bertotti, A.3    Hobor, S.4    Valtorta, E.5    Siravegna, G.6
  • 10
    • 84862999938 scopus 로고    scopus 로고
    • Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
    • Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-6.
    • (2012) Nature , vol.486 , pp. 532-536
    • Misale, S.1    Yaeger, R.2    Hobor, S.3    Scala, E.4    Janakiraman, M.5    Liska, D.6
  • 11
    • 58749102224 scopus 로고    scopus 로고
    • High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice
    • SantiniD, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, et al.High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice. Oncologist 2008;13: 1270-5.
    • (2008) Oncologist , vol.13 , pp. 1270-1275
    • Santini, D.1    Loupakis, F.2    Vincenzi, B.3    Floriani, I.4    Stasi, I.5    Canestrari, E.6
  • 12
    • 79952698311 scopus 로고    scopus 로고
    • External quality assessment for KRAS testing is needed: Setup of a European program and report of the first joined regional quality assessment rounds
    • Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, de Stricker K, et al. External quality assessment for KRAS testing is needed: Setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 2011;16:467-78.
    • (2011) Oncologist , vol.16 , pp. 467-478
    • Bellon, E.1    Ligtenberg, M.J.2    Tejpar, S.3    Cox, K.4    De Hertogh, G.5    De Stricker, K.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.